EPIDEMIOLOGY OF ISOTRETINOIN EXPOSURE DURING PREGNANCY

被引:83
|
作者
DAI, WS [1 ]
LABRAICO, JM [1 ]
STERN, RS [1 ]
机构
[1] HARVARD UNIV,BETH ISRAEL HOSP,SCH MED,DEPT DERMATOL,BOSTON,MA 02215
关键词
D O I
10.1016/0190-9622(92)70088-W
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Background: Exposure to isotretinoin during pregnancy is associated with a high risk of major fetal malformations. Objective: Our purpose was to determine the reasons for and outcomes of in utero isotretinoin exposure. Methods: On the basis of 433 spontaneous reports, we describe the likely reasons these exposures occurred and the outcomes of these pregnancies. In our analysis of the outcomes of pregnancy, we separately consider the pregnancies known to us before their outcomes were determined as prospective cases. Results: Timing of conception in relation to initiation of therapy with isotretinoin was known for 396 women. Of these, 130 patients (33%) were already pregnant when they started isotretinoin. An additional 65 patients (16%) became pregnant in the first 3 weeks of isotretinoin use. Pregnancy outcomes were known on 409 pregnancies. Among these, 222 (54%) ended in elective abortion and 29 (7%) in spontaneous or missed abortion. Of 151 births, 72 (48%) were normal, 71 (47%) had congenital malformations, and 8 (5%) had abnormalities other than malformations. Of 94 prospectively ascertained pregnancies that ended in births, 28% had congenital malformations (95% confidence interval 19% to 37%). Exposure to isotretinoin during any time and for as little as one capsule within the first trimester have been associated with congenital malformations. Conclusion: The high proportion of exposures in already or recently pregnant women illustrates the importance of obtaining a negative pregnancy test before the initiation of isotretinoin therapy and of delaying the commencement of isotretinoin therapy until the onset of the next menstrual period. Furthermore, the importance of reliable contraceptive methods should be emphasized to patients when isotretinoin is prescribed. Young women seem to be at an especially high risk of pregnancy exposure to isotretinoin. There is a substantial risk of congenital malformation at all therapeutic doses of isotretinoin, even when the duration of exposure is brief.
引用
收藏
页码:599 / 606
页数:8
相关论文
共 50 条
  • [31] Epoprostenol Exposure During Pregnancy
    Naoum, Emily E.
    LaVita, Carolyn
    Lopez, Natasha
    Nardone, Alexa
    Soffer, Marti D.
    Shelton, Kenneth T.
    CRITICAL CARE EXPLORATIONS, 2023, 5 (06) : E0928
  • [32] Radiation exposure during pregnancy
    Fiebich, Martin
    Zink, Klemens
    ONKOLOGE, 2018, 24 (07): : 545 - 551
  • [33] Exposure to sibutramine during pregnancy
    Garcia-Bournissen, Facundo
    Shrim, Alon
    Koren, Gideon
    CANADIAN FAMILY PHYSICIAN, 2007, 53 : 229 - 230
  • [34] Exposure to Tamoxifen During Pregnancy
    Simsek, Tayup
    Sever, Baris
    JOURNAL OF THE TURKISH-GERMAN GYNECOLOGICAL ASSOCIATION, 2008, 9 (03) : 168 - 170
  • [35] Fluconazole exposure during pregnancy
    Kaplan, Yusuf Cem
    Koren, Gideon
    Bozzo, Pina
    CANADIAN FAMILY PHYSICIAN, 2015, 61 (08) : 685 - 686
  • [36] Fluvastatin exposure during pregnancy
    Seguin, J
    Samuels, P
    OBSTETRICS AND GYNECOLOGY, 1999, 93 (05): : 847 - 847
  • [37] Pregnancies and Pregnancy Outcomes during Isotretinoin Treatment in Four Canadian Provinces
    Henry, David
    Dormuth, Colin
    Winquist, Brandy
    Bugden, Shawn
    Platt, Robert
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2015, 24 : 254 - 254
  • [38] Radiation exposure during pregnancy
    Raabe, Andreas
    Mueller, Wolfgang-Ulrich
    NEUROSURGICAL REVIEW, 2008, 31 (03) : 351 - 352
  • [39] Radiation exposure during pregnancy
    Andreas Raabe
    Wolfgang-Ulrich Müller
    Neurosurgical Review, 2008, 31 : 351 - 352
  • [40] RABIES EXPOSURE DURING PREGNANCY
    SPENCE, MR
    DAVIDSON, DE
    DILL, GS
    BOONTHAI, P
    SAGARTZ, JW
    AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 1975, 123 (06) : 655 - 656